XML 22 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
DIVESTITURES (Notes)
 9 Months Ended
Sep. 30, 2018
Acquisitions and Divestitures [Abstract]  
Mergers, Acquisitions and Dispositions Disclosures [Text Block]
DIVESTITURES AND LICENSING ARRANGEMENTS

Divestitures

The following table summarizes proceeds, gains and royalty income resulting from divestitures. Revenues and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains).

 
Three Months Ended September 30,
 
Proceeds(a)
 
Divestiture Gains
 
Royalty Income
Dollars in Millions
2018
 
2017
 
2018
 
2017
 
2018
 
2017
Manufacturing Operations
$
—

 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

Diabetes Business
165

 
82

 
—

 
—

 
(170
)
 
(78
)
Erbitux* Business
59

 
54

 
—

 
—

 
(48
)
 
(56
)
Mature Brands and Other
140

 
1

 
(108
)
 
1

 
1

 
(2
)
 
$
364

 
$
137

 
$
(108
)
 
$
1

 
$
(217
)
 
$
(136
)
 
Nine Months Ended September 30,
 
Proceeds(a)
 
Divestiture Gains
 
Royalty Income
Dollars in Millions
2018
 
2017
 
2018
 
2017
 
2018
 
2017
Manufacturing Operations
$
159

 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

Diabetes Business
408

 
333

 
—

 
(100
)
 
(497
)
 
(252
)
Erbitux* Business
168

 
162

 
—

 
—

 
(145
)
 
(164
)
Mature Brands and Other
212

 
31

 
(178
)
 
(26
)
 
(2
)
 
(4
)
 
$
947

 
$
526

 
$
(178
)
 
$
(126
)
 
$
(644
)
 
$
(420
)

(a)
Includes royalties received subsequent to the related sale of the asset or business.
Manufacturing Operations
In the fourth quarter of 2017, BMS sold its small molecule active pharmaceutical ingredient manufacturing operations in Swords, Ireland to SK Biotek for approximately $165 million, subject to certain adjustments. The transaction was accounted for as the sale of a business. SK Biotek will provide certain manufacturing services for BMS through 2022.
Diabetes Business
In the first quarter of 2017, BMS received $100 million from AstraZeneca as additional contingent consideration for the diabetes business divestiture upon achievement of a regulatory approval milestone, which was included in Other income (net).
Mature Brands and Other
Divestitures include several brands sold to Cheplapharm resulting in proceeds of $153 million and divestiture gains of $127 million in 2018.

Licensing Arrangements

Biogen
In the second quarter of 2017, BMS out-licensed to Biogen exclusive rights to develop and commercialize BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy. Biogen paid $300 million to BMS which was included in Other income (net). BMS is also entitled to contingent development, regulatory and sales-based milestone payments of up to $410 million if achieved and future royalties. BMS originally acquired the rights to this compound in 2014 through its acquisition of iPierian. Biogen assumed all of BMS’s remaining obligations to the former stockholders of iPierian.
Roche
In the second quarter of 2017, BMS out-licensed to Roche exclusive rights to develop and commercialize BMS-986089, an anti-myostatin adnectin in development for Duchenne Muscular Dystrophy. Roche paid $170 million to BMS which was included in Other income (net). BMS is also entitled to contingent development and regulatory milestone payments of up to $205 million if achieved and future royalties.